The aim of the study was to assess expression immune checkpoint inhibitor programmed death-ligand 1 (PD-L1) in equine sarcoids (ES). Programmed is expressed by various cancer cells block T cell–mediated elimination tumor cells. Antibodies targeting human PD-L1 were tested immunohistochemistry for their cross-reactivity with using formalin-fixed, paraffin-embedded tissues. Our results do not sup...

The signal transduction of human programmed death ligand 1 (PD-L1), as an important checkpoint gene in the immune system, plays a key role internal function and survival cancer cells. In this paper, PD-L1-siRNA immunostimulatory IL-2 encoding plasmid DNA loaded by polyethylenimine (PEI) lipid nanoparticles (PEI-LNPs) were constructed. Its therapeutic effect on lung was evaluated, its physical p...

acute lymphoblastic leukemia (all) is a malignant disorder of lymphoid precursor cells, which could be classified according to morphological and cytochemical methods as well as immunophenotyping. twenty patients with all, who had been referred to the children's medical center hospital, during the year 2007, were enrolled in this study in order to evaluate the morphologic and immunophenotypic pr...

Tumor immunotherapy is currently a hot research topic in the field of oncology, and an efficacious mode tumor treatment. Programmed cell death receptor PD-1 (PD-1) important immunosuppressive molecule, which mainly expressed activated T B cells. PD-1/PD-L1 inhibitors can block binding to PD-L1, negative regulatory signals, restore activity cells, thus enhancing immune response.

Programmed death-ligand 1 (PD-L1) is a surface protein overexpressed in tumor cells. Recently, targeted therapy using PD-L1 antibodies to reconstitute the antitumor activity of T cells has received considerable attention as cancer treatment. Among several types anti-PD-L1 antibodies, small-sized antibody fragments are useful agents block for experimental and therapeutic purposes owing their hig...

article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

In a very important recent study, Chen and colleagues describe that PD-L1 (B7-H1, CD274) is expressed on both malignant cells and infiltrating macrophages in a subset of aggressive B-cell lymphomas (1). The article highlights the possibilities of targeting the PD-1/PD-L1 pathway in these malignancies. Interactions between PD-1 on T cells and the ligand PD-L1 (B7-H1) control the induction and ma...

PD-L1 has been characterized as an inhibitory immune checkpoint, leading to the suppression of potential anti-tumor activities in many cancer types. In view relatively limited efficacy checkpoint blockades against breast cancer, our recent study addressed possibility that addition its immune-inhibitory functions, promotes pro-metastatic cells themselves. Indeed, published findings demonstrated ...

Both positive and negative regulatory roles have been suggested for the B7 family member PD-L1(B7-H1). PD-L1 is expressed on antigen-presenting cells (APCs), activated T cells, and a variety of tissues, but the functional significance of PD-L1 on each cell type is not yet clear. To dissect the functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1(-/-)) mice. CD4(+) and CD8(+) T cell r...

PD-L1 (CD274) contributes to functional exhaustion of T cells and limits immune responses in patients with cancer. In this study, we report the identification of an human leukocyte antigen (HLA)-A2-restricted epitope from PD-L1, and we describe natural, cytolytic T-cell reactivity against PD-L1 in the peripheral blood of patients with cancer and healthy individuals. Notably, PD-L1-specific T ce...